GlobeNewswire

Lyell Immunopharma to Present Positive Updated Ronde-Cel Data in More than 80 Patients at ASH 2026 from PiNACLE Pivotal Trial in 3L+ and from Phase 1/2 2L Cohort in Patients with Relapsed/Refractory Large B-Cell Lymphoma
04/11/2026
Ronde-cel achieved a 91% overall response rate and 77% complete response rate; median progression-free survival not reached and estimated 6-month duration of complete response of 92% in 44 patients with 3L+ R/R LBCL in [...]
Agios to Highlight Strength and Differentiation of Rare Hematology Portfolio with New Clinical Data for Mitapivat in Sickle Cell Disease and AG-236 in Polycythemia Vera at ASH 2026
04/11/2026
14 abstracts accepted at ASH 2026, including three oral presentations featuring new data across mitapivat clinical programs New analyses from RISE UP Phase 3 trial of mitapivat in sickle cell disease show durable [...]
CRISPR Therapeutics to Present Clinical Data from Zugo-cel in Large B-Cell Lymphoma at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition
04/11/2026
ZUG, Switzerland and BOSTON, Nov. 04, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that clinical data in patients with relapsed or refractory large B-cell lymphoma from the ongoing Phase 1 [...]
Lakefront Biotherapeutics Announces Poster Presentation at the 2026 American Society of Hematology Meeting
04/11/2026
Gamgertamig data from ongoing Phase 1b studies suggest potential to retain remission after B cell reconstitution, maintained in the absence of background therapy for autoimmune cytopenias, consistent with an “immune [...]
Lyell Immunopharma Announces $80 Million Private Placement to Advance Ronde-Cel Toward Planned BLA Submission
04/11/2026
Investors include ARCH Venture Partners, Adage Capital Management LP, Caligan Partners LP, RTW Investments, a leading mutual fund and other new and existing institutional investors. Ronde-cel, a next-generation CD19/ [...]
Solu Therapeutics to Present Initial Phase 1 Results of STX-0712 and New Preclinical Data on STX-0640 in Two Oral Presentations at the 2026 ASH Annual Meeting
04/11/2026
BOSTON, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Solu Therapeutics, a biotechnology company pioneering novel therapies to eliminate disease-driving cells in cancer and immunology, today announced that initial results from its [...]
Kura Oncology and Kyowa Kirin to Present First Ziftomenib-FLT3 Inhibitor Clinical Data at ASH 2026
04/11/2026
– Two oral presentations to feature first ziftomenib combination data with quizartinib in newly diagnosed and gilteritinib in relapsed/refractory NPM1/FLT3 co-mutated AML – – Longer-term Phase 1b data for ziftomenib [...]
Hemab Therapeutics to Present Clinical and Preclinical Data from Multiple Blood Coagulation Programs at the 68th ASH Annual Meeting and Exposition
04/11/2026
First clinical data for sutacimig in Factor VII deficiency (FVIID) shows multi-fold accumulation of endogenous FVII(a) with shortening of prothrombin time after a single subcutaneous dose in initial participants of the [...]
Daré Bioscience to Present at Stifel’s 2026 Healthcare Conference
04/11/2026
SAN DIEGO, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world [...]
Tangram Announces Oral Presentation of TGM-148 Preclinical Data Highlighting Context-Dependent Mechanism of Action at the American Society of Hematology (ASH) 2026 Annual Meeting
04/11/2026
TGM-148 enhances thrombin generation in impaired hemostasis No thrombotic safety signals at repeat toxicology doses in healthy non-human primates Phase 1 trial in healthy volunteers underway, with initial data [...]
Disc Medicine Announces Multiple Presentations Across Portfolio at the 68th American Society of Hematology (ASH) Annual Meeting
04/11/2026
Two oral presentations featuring additional data from RALLY-MF Phase 2 trial of selcodebart (DISC-0974) in anemia of myelofibrosis (MF) and RESTORE-PV Phase 2 trial of DISC-3405 in polycythemia vera (PV) Oral [...]
Cullinan Therapeutics Announces Presentations for CLN-049, a FLT3 T Cell Engager, and Velinotamig, a BCMA T Cell Engager, at the 68th ASH Annual Meeting
04/11/2026
CAMBRIDGE, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell [...]
Immix Biopharma’s NXC-201 NEXICART-2 Interim Clinical Trial Results Selected for Oral Presentation at ASH 2026
04/11/2026
– Data will be presented on Monday, December 14, 2026 at 11:15 AM CDT – LOS ANGELES, CA, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“Immix”, “Company”, “We” or “Us” or ”IMMX”), a global leader in AL [...]
Applied Biologics Announces Full Enrollment of BIOxHEAL™ Phase 3 Sentinel Safety Cohort
04/11/2026
Completion of sentinel cohort enrollment triggers independent Data and Safety Monitoring Board review, a required milestone before initiation of the 243-patient randomized controlled phase SCOTTSDALE, Ariz., Nov. 04, [...]
Metagenomi Therapeutics to Present Preclinical Data Supporting MGX-001, a Potential One-Time Therapy for Hemophilia A, in Oral Presentation at 68th American Society of Hematology Annual Meeting
04/11/2026
MGX-001 data establish preclinical proof-of-concept in hemophilia A On track to initiate global clinical trial in 2027 EMERYVILLE, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (Nasdaq: MGX) ( [...]
Translational Data from Anal Cancer Patients Show Pelareorep Drives HPV-Specific Immune Responses, Supporting its Potential Across HPV-Driven Cancers
04/11/2026
Pelareorep-driven changes in the tumor microenvironment are associated with tumor responses and shrinkage Immune activation levels more than doubled in nearly all patients after one cycle of treatment Substantial [...]
ORYZON to Present Updated Positive Clinical Data for Iadademstat in Hematological Malignancies at ASH 2026
04/11/2026
Three iadademstat abstracts have been accepted for presentation Updated data from the ongoing Phase Ib ALICE-2 trial combining iadademstat with azacitidine and venetoclax in newly diagnosed, unfit AML patients showed a [...]
J-Star Holding Co., Ltd. Provides Update on Capital Structure Authorization and Strategic Execution Timeline
04/11/2026
TAICHUNG, Taiwan, Nov. 04, 2026 (GLOBE NEWSWIRE) -- J-Star Holding Co., Ltd. (Nasdaq: YMAT) (“J-Star” or the “Company”), an innovator in advanced composite manufacturing, today provided a clarification regarding the [...]
Menarini Group and Ryvu Therapeutics Announce First Clinical Data from the Phase II JASPIS-01 Study of dapolsertib (MEN1703, SEL24) in Heavily Pretreated Relapsed/Refractory Aggressive B-cell non-Hodgkin Lymphoma at the 2026 ASH Annual Meeting
04/11/2026
First clinical data for dapolsertib monotherapy: initial results from the Phase II JASPIS-01 study of dapolsertib (MEN1703), a first-in-class oral dual PIM/FLT3 kinase inhibitor, in patients with relapsed/refractory (r/ [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum